1. 372 Single-agent anti-tumor activity in relapsed/refractory solid tumors: interim data from the phase 1 solid tumor trial of AMV564, a novel T-cell engager. (10th December 2020) Authors: Piha-Paul, Sarina; Starodub, Alexander; Karim, Raghad; Shafique, Michael; Suarez, Gabriel Tinoco; Ruegg, Curtis; Smith, Victoria; Chun, Patrick Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A226 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 372 Single-agent anti-tumor activity in relapsed/refractory solid tumors: interim data from the phase 1 solid tumor trial of AMV564, a novel T-cell engager. (9th November 2020) Authors: Piha-Paul, Sarina; Starodub, Alexander; Karim, Raghad; Shafique, Michael; Suarez, Gabriel Tinoco; Ruegg, Curtis; Smith, Victoria; Chun, Patrick Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A397 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 692 AMV564, a clinically active T cell engager, induces a target-dependent adaptive immune response. (10th December 2020) Authors: Eckard, Sterling; Sarde, Aurelien; Mei, Li; Ruegg, Curtis; Chun, Patrick; Smith, Victoria Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A416 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 692 AMV564, a clinically active T cell engager, induces a target-dependent adaptive immune response. (9th November 2020) Authors: Eckard, Sterling; Sarde, Aurelien; Mei, Li; Ruegg, Curtis; Chun, Patrick; Smith, Victoria Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A733 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗